Effects of hydrogen-rich water on blood uric acid in patients with hyperuricemia: A randomized placebo-controlled trial
Wu F et al. · Heliyon. 2024;10(16):e36401.
What kind of evidence is this?
Human
Randomized placebo-controlled three-arm trial
Metabolic and lipid health
H₂-rich water
Not reported in this record.
Not reported in this record.
Methods at a glance
Adults with hyperuricemia
100 completed: placebo n=32, low-dose n=35, high-dose n=33
8 weeks; assessments at weeks 4 and 8
Low dose: two 330 mL H₂-water bottles plus one ordinary-water bottle daily. High dose: three 330 mL H₂-water bottles daily.
H₂ dissolved in water — H₂ only, not Brown’s gas.
H₂ concentration at least 4.66 mg/L. The high-dose group received approximately 4.61 mg H₂/day.
Not applicable — oral water, not gas inhalation.
No O₂ was co-delivered as part of the intervention.
Three 330 mL bottles/day of ordinary drinking water
Outcomes and reported result
Blood uric acid, dose and time response, safety
Uric acid fell within the high-dose group from 488.2 to 446.8 μmol/L at week 8. However, the proportions achieving at least a 10% reduction did not differ significantly between placebo, low-dose and high-dose groups.
Methods, main results and trial registration checked in the free full text; independent appraisal remains incomplete.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
The highlighted reduction is a within-group result. The categorical responder comparisons between groups were not significant, so superiority over placebo is not established by that analysis.
Adults with hyperuricemia meeting this trial’s criteria.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 39258191 · DOI: 10.1016/j.heliyon.2024.e36401
Open-access article.
Free full text on PMC and publisher page; identifiers cross-checked in PubMed.
2026-08-10